Brief: Transgene Presents Initial Phase I Data Of TG6002

Transgene SA

09/04/2021 07:16

April 9 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE PRESENTS INITIAL PHASE I DATA OF TG6002,
HIGHLIGHTING
THE POTENTIAL OF THE INTRAVENOUS ADMINISTRATION OF ITS ONCOLYTIC
VIRUSES
    * DETAILED RESULTS TO BE PRESENTED AT AACR 2021 ANNUAL
CONGRESS
    * DATA CONFIRM THAT CHEMOTHERAPY AGENT 5-FU IS PRODUCED IN
PATIENTS' TUMORS AFTER INTRAVENOUS ADMINISTRATION
    * INTRAVENOUS ADMINISTRATION COULD ALLOW ONCOLYTIC VIRUSES
FROM
TRANSGENE'S INVIR.IO™ PLATFORM TO BE USED TO TREAT A BROAD RANGE
OF SOLID TUMORS

Source text for Eikon:  ID:nBw5xkqf4a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))